Chemical subgroup
A10BD – Kombinationen oraler blutzuckersenkender Mittel
10Decisions
27Patient groups
Added benefit by patient group
- Minor3
- Not proven24
Decisions, newest first
- 2019-12-19XigduoDapagliflozin/MetforminMinor: 3 of 6 patient groupsNot proven: 3 of 6 patient groups
- 2019-11-22GlyxambiEmpagliflozin/LinagliptinNot proven
- 2018-11-01SteglujanErtugliflozin/SitagliptinNot proven
- 2018-02-01KomboglyzeSaxagliptin/MetforminNot proven
- 2016-12-15JanumetSitagliptin/MetforminNot proven: 3 of 3 patient groups
- 2016-12-15KomboglyzeSaxagliptin/MetforminNot proven: 2 of 2 patient groups
- 2016-09-01SynjardyEmpagliflozin/MetforminNot proven: 6 of 6 patient groups
- 2015-02-05VokanametCanagliflozin/MetforminNot proven: 3 of 3 patient groups
- 2013-10-01KomboglyzeSaxagliptin/MetforminNot proven
- 2013-10-01EucreasVildagliptin/MetforminNot proven: 3 of 3 patient groups
Data status: 2026-10-29